Park Capital Management LLC WI Has $379,000 Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Park Capital Management LLC WI boosted its position in shares of Eli Lilly and Company (NYSE:LLY) by 7.5% during the 1st quarter, HoldingsChannel reports. The fund owned 459 shares of the company’s stock after buying an additional 32 shares during the quarter. Park Capital Management LLC WI’s holdings in Eli Lilly and Company were worth $379,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. Brown Lisle Cummings Inc. grew its holdings in shares of Eli Lilly and Company by 4.5% during the 1st quarter. Brown Lisle Cummings Inc. now owns 3,424 shares of the company’s stock worth $2,828,000 after purchasing an additional 146 shares in the last quarter. HWG Holdings LP acquired a new position in shares of Eli Lilly and Company in the first quarter valued at $201,000. Palumbo Wealth Management LLC bought a new position in Eli Lilly and Company in the first quarter worth $411,000. M3 Advisory Group LLC lifted its position in Eli Lilly and Company by 8.2% in the first quarter. M3 Advisory Group LLC now owns 606 shares of the company’s stock worth $501,000 after purchasing an additional 46 shares during the period. Finally, Live Oak Private Wealth LLC boosted its stake in Eli Lilly and Company by 37.7% during the first quarter. Live Oak Private Wealth LLC now owns 2,705 shares of the company’s stock worth $2,234,000 after buying an additional 741 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analyst Ratings Changes

LLY has been the subject of a number of recent research reports. Wall Street Zen upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Saturday, June 7th. Guggenheim reissued a “buy” rating and issued a $936.00 price target on shares of Eli Lilly and Company in a research report on Friday. Wells Fargo & Company restated an “overweight” rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. Erste Group Bank downgraded Eli Lilly and Company from a “buy” rating to a “hold” rating in a report on Thursday, June 5th. Finally, UBS Group lowered their price objective on Eli Lilly and Company from $1,100.00 to $1,050.00 and set a “buy” rating on the stock in a research note on Friday, May 2nd. One investment analyst has rated the stock with a sell rating, three have given a hold rating and eighteen have assigned a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $1,011.79.

Eli Lilly and Company Trading Up 1.0%

LLY opened at $770.16 on Tuesday. Eli Lilly and Company has a 1-year low of $677.09 and a 1-year high of $972.53. The stock has a market capitalization of $729.91 billion, a PE ratio of 62.67, a PEG ratio of 1.11 and a beta of 0.41. The company has a current ratio of 1.37, a quick ratio of 1.06 and a debt-to-equity ratio of 2.18. The firm has a 50-day moving average price of $780.81 and a two-hundred day moving average price of $800.36.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing analysts’ consensus estimates of $4.64 by ($1.30). Eli Lilly and Company had a net margin of 22.67% and a return on equity of 85.51%. The company had revenue of $12.73 billion during the quarter, compared to analyst estimates of $12.77 billion. During the same period in the prior year, the business earned $2.58 EPS. The business’s revenue for the quarter was up 45.2% on a year-over-year basis. As a group, equities analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th will be given a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.78%. Eli Lilly and Company’s payout ratio is currently 48.82%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.